<DOC>
	<DOCNO>NCT00003441</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness irofulven treat patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Irofulven Treating Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess antitumor activity 6-hydroxymethylacylfulvene ( MGI-114 ) give daily 5 day every 28 day patient metastatic adenocarcinoma colon rectum . II . Evaluate qualitative quantitative toxicity MGI-114 give schedule patient population . OUTLINE : Patients receive 6-hydroxymethylacylfulvene ( MGI-114 ) IV 5 minute daily 5 consecutive day . Courses repeat every 28 day . The minimum treatment period 2 course . Treatment continue indefinitely absence unacceptable toxic effect disease progression . Patients follow end every course study , every 3 month thereafter death . PROJECTED ACCRUAL : A total 18-35 patient accrue study within 6-10 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irofulven</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma colon rectum Bidimensionally measurable lesion Sentinel lesion outside field prior radiation therapy No confirm suspect brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 01 Life expectancy : At least 12 week Hematopoietic : Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No active congestive heart failure No uncontrolled angina At least 6 month since prior myocardial infarction No uncontrolled hypertension Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent serious infection No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No overt psychosis mental disability No life threaten illness ( unrelated tumor ) PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent biologic therapy Chemotherapy : No prior chemotherapy metastatic disease At least 6 month since prior adjuvant chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiation therapy recover No concurrent radiotherapy Surgery : At least 4 week since prior major surgery recover No concurrent surgery Other : At least 28 day since prior administration investigational drug No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>6-hydroxymethylacylfulvene</keyword>
	<keyword>MGI-114</keyword>
	<keyword>Irofulven</keyword>
</DOC>